Expertise in
3
conditions

Vincenzo Libri

Gower Street, 
London, ENG, GB 
Expertise in
3
conditions
Gower Street, 
London, ENG, GB 

Overview

Vincenzo Libri practices practicing medicine in London, United Kingdom.

Mr. Libri is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Severe Acute Respiratory Syndrome (SARS), Primary Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and COVID-19.

He is actively involved in clinical research, co-authoring 49 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Gower Street, London, ENG, United Kingdom
Other Locations
Queen Square, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19
A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Biological
Study Drugs: ChAdOx1 COVID-19 Vaccine, MenACWY COVID-19 Vaccine, Paracetamol
Study Phase: Phase 2/Phase 3
A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease
A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease
Enrollment Status: Completed
Publish Date: April 15, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

46 Total Publications

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.
ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses.
Journal: Vaccine
Published: March 19, 2026

Frequently Asked Questions about Vincenzo Libri

Is Vincenzo Libri a top-rated expert for Severe Acute Respiratory Syndrome (SARS)?

MediFind is an objective health platform that identifies experts based on real-world data. Vincenzo Libri is classified as an Advanced expert for Severe Acute Respiratory Syndrome (SARS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Vincenzo Libri participate in research or clinical trials?

Yes. Vincenzo Libri has published 46 articles and abstracts on conditions like Severe Acute Respiratory Syndrome (SARS). You can view a list of Vincenzo Libri's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Libri's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile